D-dimer XDP correlates with fibrinolytic shutdown in renal transplant patients treated with anti-T-cell antibodies.
Goldman
M H
MH
Department of Surgery, University of Tennessee Medical Center, Knoxville 37920.
McGrath
G
G
Freeman
M
M
Stevens
S
S
Chen
J P
JP
D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005342:Fibrinolysis; D006736:Horses; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D051379:Mice; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010960:Plasminogen Activators / Q000097:blood; D011817:Rabbits; D013601:T-Lymphocytes / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000961:Antilymphocyte Serum; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D016853:Muromonab-CD3; D017395:Plasminogen Activator Inhibitor 1; D014409:Tumor Necrosis Factor-alpha; D010960:Plasminogen Activators